WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 300250

CAS#: 51333-22-3

Description: Budesonide is a glucocorticoid steroid for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis. Additionally, it is used for Crohn's disease (inflammatory bowel disease). It is marketed by AstraZeneca as a nasal inhalant under the brand name Rhinocort (in Denmark, as Rhinosol), as an oral inhalant under the brand name Pulmicort (in Israel, Budicort), and as either an enema or a modified release oral capsule under the brand name Entocort. It is also sold in combination with formoterol (Oxis) in a single inhaler, under the brand name Symbicort.

Chemical Structure

CAS# 51333-22-3

Theoretical Analysis

MedKoo Cat#: 300250
Name: Budesonide
CAS#: 51333-22-3
Chemical Formula: C25H34O6
Exact Mass: 430.24
Molecular Weight: 430.530
Elemental Analysis: C, 69.74; H, 7.96; O, 22.30

Price and Availability

Size Price Availability Quantity
100mg USD 90 Ready to ship
200mg USD 150 Ready to ship
500mg USD 300 Ready to ship
1g USD 500 Ready to ship
2g USD 850 Ready to ship
Bulk inquiry

Synonym: S 1320; S-1320; S1320; Spirocort; Rhinocort; Budesonide;

IUPAC/Chemical Name: (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5] indeno[1,2-d][1,3]dioxol-4(2H)-one


InChi Code: InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1

SMILES Code: O=C(C=C[C@@]12C)C=C1CC[C@@]([C@]2([H])[C@@H](O)C[C@@]34C)([H])[C@]3([H])C[C@]5([H])[C@@]4(C(CO)=O)OC(CCC)O5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:
Biological target: Budesonide, an inhaled glucocortical steroid, is an orally active glucocorticoid receptor agonist.
In vitro activity: In vitro studies were performed on normal CHO-K1 cells that were treated with budesonide at concentrations of 0.5 μM - 45 μM. After 48 hours of incubation with the test agent, the samples were prepared for optical microscopy using the H&E method and transmission electron microscopy. Comparison of cells exposed to budesonide with control cells (without addition of test agent) revealed vacuolization changes with autophagy. Apoptotic changes have also been demonstrated, which occured to a lesser extent than vacuolization. The changes observed after budesonide treatment in the cytological picture of patients with allergic rhinitis indicate the therapeutic effect of this drug. On the other hand, the changes observed in the cytoplasm of epithelial cells, such as autophagy (clearly promoted in CHO-K1 cells) and leucophagocytosis, may indicate an additional mechanism of action for budesonide. Reference: J Physiol Pharmacol. 2017 Dec;68(6):907-919. http://www.jpp.krakow.pl/journal/archive/12_17/pdf/907_12_17_article.pdf
In vivo activity: To assess the effects of budesonide on the survival of mice with ALI, a lethal dose of LPS (40 mg/kg) was injected (i.t.), which resulted in about 70% death within 72 h (Figure 5, P < 0.01). The mortality rate dropped to 25% in the budesonide-treated group (Figure 5, P < 0.01). These findings suggested that budesonide improved the survival of ALI mice. The results showed that the components of the NLRP3 inflammasome, including NLRP3, pro-caspase-1, pro-IL-1β, and pro-IL-18, were significantly increased in the lungs of mice with LPS-induced ALI (Figures 6(a)–6(g), P < 0.01). Budesonide pretreatment partially restored these effects, indicating inhibition of the NLRP3 inflammasome (Figures 6(a)–6(g), P < 0.05). Additionally, budesonide also dramatically reduced NLRP3 inflammasome activation by modulating the expression of caspase-1 p20 and the secretion of IL-1β and IL-18 (Figures 6(c), 6(e), and 6(h)–6(i); P < 0.05). Taken together, these data indicated that inhibition of NLRP3 inflammasome activation contributed to the protective effects of budesonide against LPS-induced ALI in mice. Reference: J Immunol Res. 2019 Feb 27;2019:7264383. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30937316/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 25.0 58.10

Preparing Stock Solutions

The following data is based on the product molecular weight 430.530000000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol: 1. Trybus E, Krol G, Obarzanowski T, Trybus W, Kopacz-Bednarska A, Obarzanowski M, Krol T. In vivo and in vitro studies on multidirectional mechanism of anti-allergic activity of budesonide. J Physiol Pharmacol. 2017 Dec;68(6):907-919. PMID: 29550803. 2. Dong L, Zhu YH, Liu DX, Li J, Zhao PC, Zhong YP, Chen YQ, Xu W, Zhu ZQ. Intranasal Application of Budesonide Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Nucleotide-Binding Oligomerization Domain-Like Receptor Family, Pyrin Domain-Containing 3 Inflammasome Activation in Mice. J Immunol Res. 2019 Feb 27;2019:7264383. doi: 10.1155/2019/7264383. PMID: 30937316; PMCID: PMC6415278.
In vivo protocol: 1. Dong L, Zhu YH, Liu DX, Li J, Zhao PC, Zhong YP, Chen YQ, Xu W, Zhu ZQ. Intranasal Application of Budesonide Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Nucleotide-Binding Oligomerization Domain-Like Receptor Family, Pyrin Domain-Containing 3 Inflammasome Activation in Mice. J Immunol Res. 2019 Feb 27;2019:7264383. doi: 10.1155/2019/7264383. PMID: 30937316; PMCID: PMC6415278.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Hintong T, Chongvisal S, Pipanmekaporn T, Unchiti K. A Randomized Comparison of Effects of Budesonide Spray and K-Y Gel as an Endotracheal Tube Cuff Lubricant on Incidence of Postoperative Sore Throat. J Perianesth Nurs. 2023 Jan 5:S1089-9472(22)00546-9. doi: 10.1016/j.jopan.2022.10.003. Epub ahead of print. PMID: 36610870. 2: Zhang M, Li Q, Li L, Guo X, Wang X, Han X, Liang L, Miao M, Zhang F, Wang J, Wu Y, Yu C. The Efficacy of N-Acetylcysteine Combined With Budesonide/Formoterol in the Treatment of Stable Chronic Obstructive Pulmonary Disease. Am J Ther. 2022 Nov-Dec 01;29(6):e687-e690. doi: 10.1097/MJT.0000000000001290. Epub 2021 Jan 29. PMID: 36608067. 3: D'Amico V, Arduino I, Vacca M, Iacobazzi RM, Altamura D, Lopalco A, Rizzi R, Cutrignelli A, Laquintana V, Massimo F, De Angelis M, Denora N, Lopedota AA. Colonic budesonide delivery by multistimuli alginate/Eudragit® FS 30D/inulin- based microspheres as a paediatric formulation. Carbohydr Polym. 2023 Feb 15;302:120422. doi: 10.1016/j.carbpol.2022.120422. Epub 2022 Nov 30. PMID: 36604084. 4: Daferera N, Nyström S, Hjortswang H, Ignatova S, Jenmalm MC, Ström M, Münch A. Mucosa associated invariant T and natural killer cells in active and budesonide treated collagenous colitis patients. Front Immunol. 2022 Dec 15;13:981740. doi: 10.3389/fimmu.2022.981740. PMID: 36591297; PMCID: PMC9798420. 5: Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, Aurivillius M, Patel M, Dorinsky P. Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022 Dec 6;17:3061-3073. doi: 10.2147/COPD.S374670. PMID: 36510486; PMCID: PMC9738173. 6: Gummlich BPM, Seif Amir Hosseini A, Schwörer H. Budesonide with Low-Dose 6-Mercaptopurine as a Possible New Treatment for IgG4-Related Sclerosing Cholangitis and Systemic IgG4-Related Disease: A Case Report. Am J Case Rep. 2022 Dec 8;23:e938272. doi: 10.12659/AJCR.938272. PMID: 36476942; PMCID: PMC9745840. 7: Mishra RK, Ahmad A, Kanika, Kumar A, Vyawahare A, Sakla R, Nadeem A, Siddiqui N, Raza SS, Khan R. Caffeic Acid-Conjugated Budesonide-Loaded Nanomicelle Attenuates Inflammation in Experimental Colitis. Mol Pharm. 2023 Jan 2;20(1):172-182. doi: 10.1021/acs.molpharmaceut.2c00558. Epub 2022 Dec 6. PMID: 36472567. 8: Olszanecka-Glinianowicz M, Chudek J, Urcus A, Almgren-Rachtan A. Factors affecting the choice of budesonide in the therapy of croup, asthma and chronic obstructive pulmonary disease. Postepy Dermatol Alergol. 2022 Oct;39(5):893-901. doi: 10.5114/ada.2022.120883. Epub 2022 Nov 9. PMID: 36457671; PMCID: PMC9704461. 9: Kothiwala M, Samdani S, Grover M, Gurjar V. Efficacy of Topical High Volume Budesonide Nasal Irrigation in Post FESS Patients of Chronic Rhinosinusitis With or Without Nasal Polyposis. Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):1399-1407. doi: 10.1007/s12070-021-02509-9. Epub 2021 Apr 15. PMID: 36452810; PMCID: PMC9702420. 10: de Nigris E, Treharne C, Brighton N, Holmgren U, Walker A, Haughney J. Cost- Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study. Int J Chron Obstruct Pulmon Dis. 2022 Nov 22;17:2987-3000. doi: 10.2147/COPD.S381138. PMID: 36444374; PMCID: PMC9700475. 11: Moraes LHA, Coelho RMD, Neves Dos Santos Beozzo GP, Yoshida RAM, de Albuquerque Diniz EM, de Carvalho WB. Use of budesonide associated with a pulmonary surfactant to prevent bronchopulmonary dysplasia in premature newborns - A systematic review. J Pediatr (Rio J). 2022 Nov 25:S0021-7557(22)00124-3. doi: 10.1016/j.jped.2022.10.007. Epub ahead of print. PMID: 36436670. 12: Warzecha J, Dziekiewicz M, Bieńkowska-Tokarczyk A, Małecki M, Banaszkiewicz A. A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature. J Clin Med. 2022 Nov 14;11(22):6730. doi: 10.3390/jcm11226730. PMID: 36431208; PMCID: PMC9694526. 13: Trigueros JA, Garin N, Baloira A, Aceituno S, Calvo A, Prades M, Touron C, Martínez A, Torres C. Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain. Int J Chron Obstruct Pulmon Dis. 2022 Nov 15;17:2905-2917. doi: 10.2147/COPD.S384591. PMID: 36411773; PMCID: PMC9675425. 14: Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A, Ramos N, Perello M, Gabaldon A, Azancot MA, Bolufer M, Toapanta N, Bestard O, Agraz-Pamplona I, Soler MJ. Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice. Transpl Int. 2022 Oct 14;35:10693. doi: 10.3389/ti.2022.10693. PMID: 36311259; PMCID: PMC9613952. 15: Ali Ibrahim A, Kenyon V, Fasano A, Leonard MM. Budesonide and the Gluten Containing Elimination Diet as Treatments for Non-responsive Celiac Disease in Children. J Pediatr Gastroenterol Nutr. 2022 Nov 1;75(5):616-622. doi: 10.1097/MPG.0000000000003596. Epub 2022 Aug 22. PMID: 36305882; PMCID: PMC9627632. 16: Li Y, Yu H, Lv M, Li Q, Zou K, Lv S. Combination therapy with budesonide and N-acetylcysteine ameliorates LPS-induced ALI by attenuating neutrophil recruitment through the miR-196b-5p/Socs3 molecular axis. BMC Pulm Med. 2022 Oct 26;22(1):388. doi: 10.1186/s12890-022-02185-7. PMID: 36289489; PMCID: PMC9608916. 17: Zyryanov SK, Dyakov IN, Aisanov ZR. [Pharmacoeconomics analysis of using a fixed combination of budesonide/formoterol in patients with asthma in the health care system of the Russian Federation]. Ter Arkh. 2022 Aug 12;94(7):850-858. Russian. doi: 10.26442/00403660.2022.07.201715. PMID: 36286942. 18: Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Results from part A of the multi-center, double-blind, randomized, placebo- controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2022 Oct 19:S0085-2538(22)00836-5. doi: 10.1016/j.kint.2022.09.017. Epub ahead of print. PMID: 36270561. 19: Feng W, Chen H, Lu Y, Liu R, Yuan MY, An J, Li M, Chua LS, Kait JA, Xin L. Comparing the efficacy and safety of atomization of traditional Chinese medicine Kai Hou Jian and budesonide suspension in adult acute laryngitis: a randomized control trial. Ann Transl Med. 2022 Sep;10(18):1019. doi: 10.21037/atm-22-4305. PMID: 36267766; PMCID: PMC9577730. 20: Hussain N, Robert M, Al-Bawardy B. Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis. ACG Case Rep J. 2022 Oct 7;9(10):e00882. doi: 10.14309/crj.0000000000000882. PMID: 36237281; PMCID: PMC9553371.